---
$id: https://graph.org.ai/products/commodity/51102877
$type: Product
source: UNSPSC
code: "51102877"
title: "Ambroxol/clarithromycin"
class: "51102800"
classTitle: "Combination anti-infectives"
family: "51100000"
familyTitle: "Amebicides and trichomonacides and antiprotozoals"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Ambroxol/clarithromycin

**UNSPSC Code**: 51102877
**Class**: [Combination anti-infectives](Combination anti-infectives.mdx)
**Family**: [Amebicides and trichomonacides and antiprotozoals](../Amebicides and trichomonacides and antiprotozoals.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a combination drug composed of two constituents: a mucolytic and a macrolide antibiotic, as more fully appears. The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90]. European Medicines Agency schedules AMBROXOL in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG (base), SUB12842MIG (acefyllinate), and SUB00427MIG (hydrochloride). The term AMBROXOL is an International Non-Proprietary Name or INN. World Health Organization schedules ambroxol in its Anatomical Therapeutic Chemical (ATC) Classification (R05CB06) and in its WHO Drug Dictionary. AMBROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ambroxol under HS 29221980 and SITC 51461. US Census, for industry purposes, classifies ambroxol under NAICS 325199. The second component of this combination drug, clarithromycin(51282302), is a macrolide antibiotic with the molecular formula C38H69NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1250JIK0A, chemically known as erythromycin, 6-o-methyl- but generally known as clarithromycin {51282302}, which bears US NIH Compound Identifier 54688. European Medicines Agency schedules Clarithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06641MIG. The term CLARITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules clarithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. CLARITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clarithromycin under HS 29415000 and SITC 54139. As of Q4 2014, CLARITHROMYCIN remains the US FDA Preferred Term for this commodity. Clarithromycin bears US NLM identifiers UMLS ID C0055856 and NCI Concept Code C1054.

